Pavel M. Abramov

Pavel M. Abramov

Auto-generated profile, based on publicly available information

Pavel M. Abramov

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2018 in Advances in molecular oncology
Verified
Journal Article
Open access
PDF file
PAP. M. Abramov
P. M. Abramov
AKA. N. Katargin
A. N. Katargin
MFM. D. Fedorova
M. D. Fedorova
NKN. P. Kisseljova
N. P. Kisseljova
LPL. S. Pavlova
L. S. Pavlova
SVSvetlana Vinokurova
Svetlana Vinokurova
Background. Overexpression of the human papillomavirus oncogenes E6 and E7 is a major factor in initiation and progression of HPV-induced tumors. Inactivation of negative regulatory function of E2 protein – the main viral transcription and replication regulator – is considered to be an important mechanism leading to the viral oncogenes overexpression. It is known that the loss of E2 functions occurs due to disruption of E2 open reading frame during the viral DNA integration into a cell genome in a part of HPV-positive tumors. An alternative mechanism of E2 function blocking in tumors retained its expression can be methylation of the HPV regulatory region, since it is known that E2 is incapable to bind its methylated binding sites.The study objective is to analyze methylation of the HPV16 regulatory region and expression of the viral E6 and E7 oncogenes in E2 expressing or non-expressing clinical samples of cervical cancer.Results. It has been demonstrated that the level of the HPV16 URR methylation in E2-expressing lesions is significantly higher than that in non-expressing cervical cancer lesions. Demethylation of the HPV16 promoter in cervical cell line Caski is followed by decrease of the viral E6 и E7 oncogenes mRNA levels, supporting the hypothesis that methylation is necessary for effective E6 and E7 transcription and indicates on restitution of E2 regulatory function in E2-expressing cervical cancer cells.Conclusion. These data suggest that methylation of E2 binding sites in HPV16 regulatory region blocking E2 protein binding represents an important mechanism ensuring high level of the viral E6 and E7 oncogenes expression.

5 September 2022 in Problems of Virology
Verified
Journal Article
Open access
PDF file
NKNatalia P. Kisseljova
Natalia P. Kisseljova
MFMaria D. Fedorova
Maria D. Fedorova
AZAnastasia E. Zaikina
Anastasia E. Zaikina
NENadezhda V. Elkina
Nadezhda V. Elkina
EGEkaterina E. Goldobina
Ekaterina E. Goldobina
SVSvetlana Vinokurova
Svetlana Vinokurova
Introduction. High carcinogenic-risk human papillomaviruses (hrHPVs) are recognized as etiological agents of cervical cancer. Constant expression of the viral oncoproteins, E6 and E7, is required for maintenance of the malignant phenotype of tumor cells. The exact mechanism of regulation of viral oncogenes expression in tumor cells is not fully elucidated. The purpose: identification of viral noncoding RNAs (ncRNAs) in HPV16-positve cervical cancer. Materials and methods. The reverse transcription polymerase chain reactions were used to detect viral ncRNAs in HPV16-positve primary cervical squamous cell carcinomas and SiHa and CasKi cell lines. The knockdown technique with oligonucleotides complementary to ncRNAs was used to elucidate their functions. Results. We have identified ncRNAs transcribed in the upstream regulatory region of HPV16 in the cervical carcinoma cell lines and in 32 out 32 cervical squamous cell carcinomas with episomal or integrated forms of HPV16 DNA. Knockdown of sense or antisense strains of ncRNAs by oligonucleotides results in a decrease or increase of the E6 and E7 oncogenes mRNA levels in cells, respectively. These changes of oncogenes mRNA levels are accompanied by the modulation of the levels of the p53 protein, the main target of the E6 oncoprotein. Conclusion. The presence of regulatory ncRNAs in all examined tumors and cell lines revealed for the first time indicates their necessity for maintenance of constant expression of E6 and E7 oncogenes in them. The findings can be useful for understanding of the fundamental aspects of the viral expression regulation in HPV16-positive tumors.

1 January 2019 in Онкогинекология
Verified
Journal Article
Closed access
PAPavel M. Abramov
Pavel M. Abramov
SVSvetlana Vinokurova
Svetlana Vinokurova
DEDanila S. Elkin
Danila S. Elkin
Цель исследования. Провести систематический анализ литературы на тему метилирования ДНК при раке яичников (РЯ). Особое внимание уделить работам, посвященным метилированию ДНК в качестве диагностического маркера РЯ. Материалы и методы. В обзор литературы были включены англоязычные публикации, доступные в базе данных PubMed за последние 20 лет. Результаты. Анализ данных литературы показал, что дифференциальное метилирование ДНК наблюдается в клинических образцах больных РЯ. Сегодня изучение метилирования ДНК является одним из наиболее перспективных направлений в разработке ранней диагностики РЯ. Дифференциальное метилирование ДНК не только может детектироваться в опухолевой ткани, но и выявляется с использованием неинвазивных методов. Несмотря на успехи в этой области, данные литературы носят спорадический характер. Множество сайтов метилирования генов описаны в единичных публикациях. Но есть и хорошо изученные, часто встречающиеся гены, которые описаны во многих работах: RASSF1, BRCA1, MGMT, OPCML, а также гены группы HOX. Заключение. Изучение аберрантного метилирования ДНК в опухолевой ткани и биологических жидкостях позволит разработать подход для ранней диагностики РЯ. Более того, аберрантное метилирование ДНК имеет потенциал использования в качестве прогностического маркера течения заболевания, а также маркера выбора...

15 December 2019 in Advances in molecular oncology
Verified
Journal Article
Open access
PDF file
NLN. L. Lazarevich
N. L. Lazarevich
PAP. M. Abramov
P. M. Abramov
MFM. D. Fedorova
M. D. Fedorova
IKI. F. Kustova
I. F. Kustova
DSD. A. Shavochkina
D. A. Shavochkina
ЮПЮ. И. Патютко
Ю. И. Патютко
Background. Over 600,000 people die from hepatocellular carcinoma (HCC) each year worldwide. The disease is often detected at advanced stages and in many cases is not curable. Early diagnostic and monitoring of HCC recurrences remains a substantial problem in clinical oncology. That determines the need for a search for highly sensitive and specific biomarkers for the non-invasive of HCC diagnostics. The objective of the study. Identification of the hypermethylated locus in the promoter region of the septin 9 (Sept9) gene based on the annotated methylomes from the public databases. Experimental validation of methylation on a pilot panel of paired clinical samples of patients with HCC, as well as tissue samples from patients with benign liver tumors and lymphocytes from healthy donors. Materials and methods. To analyze the methyl data, samples of HCC from TCGA, hepatocellular adenoma from GEO (Gene Expression Omnibus) depository, peripheral blood cells and tissues of healthy donors from Methbank were used. Experimental validation of methylation levels of the identified site was carried out on a pilot panel of clinical samples by bisulphite pyrosequencing using PyroMark Q24.Results. Based on the analysis of methylome data, we selected cg20275528 site, which is characterized by high level of methylation in HCC tissues and minimal levels of methylation in non-tumor liver tissue, hepatocellular adenoma and peripheral blood of healthy donors. Experimental testing on a pilot panel of clinical specimens showed that the level of marker site methylation in HCC (42 % median) is significantly higher than in non-tumor liver tissues (3 % median) and benign neoplasms (1.5 % median) and exceeds the threshold value in HCC compared to paired samples of adjacent non-tumor liver tissue in 20 out of 30 studied cases (66.6 %). The general possibility for cg20275528 methylation detection in circulating DNA of plasma in HCC patients was shown.Conclusion. The obtained results indicate that the approach to the detection and experimental verification of diagnostically significant markers developed and tested in this study can be used to identify new differentially methylated sites and to establish new approaches for non-invasive HCC diagnosis.

Verified
Journal Article
Open access
PDF file
PAPavel Abramov
Pavel Abramov
AMAlexander Mazur
Alexander Mazur
ASAlexey Starshin
Alexey Starshin
SZSvetlana Zhenilo
Svetlana Zhenilo
EPEgor Prokhortchouk
Egor Prokhortchouk
Clear cell renal cell carcinoma (ccRCC), accounting for 80–90% of renal malignancies, is frequently driven by VHL inactivation—either through mutation or promoter hypermethylation—resulting in constitutive HIF2α activation and pseudohypoxic signaling. VHL gene inactivation is a hallmark of von Hippel–Lindau syndrome, a hereditary disorder predisposing patients to ccRCC and other tumors, underscoring its central role in disease pathogenesis. While VHL dysfunction promotes aggressive tumor phenotypes, the therapeutic potential of VHL restoration remains underexplored. Here, using the Cas9 induced VHL-mutation in the Caki-1 cell line model, we demonstrate that VHL inactivation augments hypoxia-like pathways and enhances anaerobic glycolysis. Rescue of functional VHL reversed these activation patterns and modulated the expression of genes associated with angiogenesis. Using single cell transcriptomics, we show that the VHL-positive and -negative Caki-1 cells are characterized with different proportions of benign and aggressive cells as seen by analysis of specific gene expression. Furthermore, the identified angiogenesis-related genes were linked to affect clinical outcomes in ccRCC patients, suggesting that VHL restoration may mitigate high-risk molecular features.